2 results
Approved WMOCompleted
CORE PERIODPrimary:* Evaluate the safety and tolerability of up to 24 weeks of AG-348 administration in patients with pyruvate kinase deficiency (PK deficiency).Secondary:* Evaluate the pharmacokinetics (PK) of AG-348 and the metabolite AGI-8702.*…
Approved WMOCompleted
Objective: Primary: To investigate the agreement between HBPM and ABPM for measuring BP in patients with hypertension. Secondary:a) To investigate the agreement between HBPM and daytime ABPM for measuring BP in patients treated for hypertensionb) To…